Efficacy of cisplatin and fluorouracil chemotherapy plus Jianpi Yiqi formula in the treatment of advanced gastric cancer

Purpose: To investigate the efficacy of cisplatin and fluorouracil chemotherapy in combination with the Jianpi Yiqi formula in the treatment of advanced gastric cancer.Methods: A total of 64 patients with advanced gastric cancer admitted and treated at Xianyang Central Hospital from April 2019 to October 2021 were recruited and assigned equally to chemotherapy group and combination group according to the time of admission. Chemotherapy group received cisplatin and fluorouracil, while the combination group received the Jianpi Yiqi formula based on the treatment given to the chemotherapy group. Some clinical indices were evaluated in the patients.Results: Intervention in the combination group was associated with a higher total effectiveness when compared with chemotherapy group (p < 0.05). Cisplatin and fluorouracil plus Jianpi Yiqi formula resulted in significantly higher European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) score than cisplatin with fluorouracil (p < 0.05). Furthermore, cisplatin and fluorouracil plus Jianpi Yiqi formula led to considerably higher Karnofsky Performance Scale (KPS) scores versus cisplatin with fluorouracil (p < 0.05).Conclusion: In the treatment of advanced gastric cancer, cisplatin-fluorouracil chemotherapy in conjunction with the Jianpi Yiqi formula produces remarkable efficacy. This strategy increases lesion dissolution rates, improves the quality of life and behavioral status of patients, and reduces adverse reactions, resulting in prolonged patients' progression survival (PFS) and overall survival (OS) levels.